An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants DOI Creative Commons
Deborah A. Hall, Robin M. Voigt, Thaisa M. Cantu-Jungles

и другие.

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Фев. 18, 2023

Abstract A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the and this study sought to understand utility prebiotic for use in PD patients. The first experiments demonstrate that fermentation patient stool with increased production beneficial metabolites (short chain fatty acids, SCFA) changed microbiota demonstrating capacity respond favorably prebiotics. Subsequently, an open-label, non-randomized was conducted newly diagnosed, non-medicated ( n = 10) treated participants wherein impact 10 days intervention evaluated. Outcomes well tolerated (primary outcome) safe (secondary associated biological changes microbiota, SCFA, inflammation, neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept offers scientific rationale placebo-controlled trials using ClinicalTrials.gov Identifier: NCT04512599.

Язык: Английский

Arresting microbiome development limits immune system maturation and resistance to infection in mice DOI Creative Commons
Jean‐Bernard Lubin, Jamal Green, Sarah Maddux

и другие.

Cell Host & Microbe, Год журнала: 2023, Номер 31(4), С. 554 - 570.e7

Опубликована: Март 29, 2023

Язык: Английский

Процитировано

63

Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial DOI Open Access

Hamdi Jama,

Dakota Rhys‐Jones, Michael Nakai

и другие.

Nature Cardiovascular Research, Год журнала: 2023, Номер 2(1), С. 35 - 43

Опубликована: Янв. 9, 2023

Язык: Английский

Процитировано

62

Web-based multi-omics integration using the Analyst software suite DOI
Jessica Ewald,

Guangyan Zhou,

Yao Lü

и другие.

Nature Protocols, Год журнала: 2024, Номер 19(5), С. 1467 - 1497

Опубликована: Фев. 14, 2024

Язык: Английский

Процитировано

62

The best practice for microbiome analysis using R DOI Creative Commons
Tao Wen, Guoqing Niu, Tong Chen

и другие.

Protein & Cell, Год журнала: 2023, Номер 14(10), С. 713 - 725

Опубликована: Май 2, 2023

With the gradual maturity of sequencing technology, many microbiome studies have published, driving emergence and advance related analysis tools. R language is widely used platform for data powerful functions. However, tens thousands packages numerous similar tools brought major challenges researchers to explore data. How choose suitable, efficient, convenient, easy-to-learn from has become a problem researchers. We organized 324 common classified them according application categories (diversity, difference, biomarker, correlation network, functional prediction, others), which could help quickly find relevant analysis. Furthermore, we systematically sorted integrated (phyloseq, microbiome, MicrobiomeAnalystR, Animalcules, microeco, amplicon) analysis, summarized advantages limitations, will appropriate Finally, thoroughly reviewed most content in formed suitable pipeline This paper accompanied by hundreds examples with 10,000 lines codes GitHub, can beginners learn, also analysts compare test different sorts providing an important theoretical basis practical reference development better future. All code available at GitHub github.com/taowenmicro/EasyMicrobiomeR.

Язык: Английский

Процитировано

60

An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants DOI Creative Commons
Deborah A. Hall, Robin M. Voigt, Thaisa M. Cantu-Jungles

и другие.

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Фев. 18, 2023

Abstract A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the and this study sought to understand utility prebiotic for use in PD patients. The first experiments demonstrate that fermentation patient stool with increased production beneficial metabolites (short chain fatty acids, SCFA) changed microbiota demonstrating capacity respond favorably prebiotics. Subsequently, an open-label, non-randomized was conducted newly diagnosed, non-medicated ( n = 10) treated participants wherein impact 10 days intervention evaluated. Outcomes well tolerated (primary outcome) safe (secondary associated biological changes microbiota, SCFA, inflammation, neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept offers scientific rationale placebo-controlled trials using ClinicalTrials.gov Identifier: NCT04512599.

Язык: Английский

Процитировано

58